Detection of resistance to linezolid in Staphylococcus aureus infecting orthopedic patients

Indian Journal of Pathology and Microbiology

Volumn 55, Issue 3, 2012, Pages 361-364

  Thool, Vaishali U ^a,b   Bhoosreddy, Girish L ^c   Wadher, Bharat J ^a  

^a RTM NAGPUR UNIVERSITY   (India)

^b Sevadal Mahila Mahavidyalaya ^*  (India)

^c S P College   (India)

Author keywords

Etest; linezolid resistant S. aureus; minimal inhibitory concentrations; orthopedic

Indexed keywords

CLINDAMYCIN; DEOXYRIBONUCLEASE; LINEZOLID; MANNITOL; METICILLIN; SODIUM CHLORIDE; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; DISK DIFFUSION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PUS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUNDS AND INJURIES;

EID: 84867291597     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.101745     Document Type: Article

References (29)

1. Jahoda D, Nye O, Pokam AD, Landor J, Sosna A. Linezolid in the treatment of antibiotic-resistant gram positive infections of the musculoskeletol system. Acta Chir Orthop Traumatol Czech 2006;73: 329-3.
2. Hannan A, Absar M, Usman M, Naeem T, Saleem S, Arshad M. In vitro activity of Linezolid against clinical isolates of Methicillin resistant Staphylococcus. J Ayub Med Coll Abbottabad 2009;21:106-9.
3. Bauer AW, Kirby WM, Sherris JC. Antibiotic susceptibility testing by a single disc method. Am J Pathol 1966;45:493-6.
4. Clinical and Laboratory Standards Institute M2-A9. Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
5. Tenover FC, Williams PP, Stocker S, Thompson A, Clark LA, Limbago B, et al. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 2007;45:2917-22.
6. Clinical and Laboratory Standards Institute. M7-A7 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
7. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
8. Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:546-55.
9. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 2010;50:665-72.
10. Stefania S, Dafne B, Gino M, Floriana C. Linezolid Resistance in Staphylococci. Pharmaceuticals 2010;3:1988-2006.
11. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA. In Abstracts of the Thirty Eighth San Diego, CA, USA: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998. Abstract C-104, p. 98. American Society for Microbiology, Washington, DC, US.A.
12. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:1-6.
13. Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandam P. Prevalence and antimicrobial susceptibility pattern of Methicillin resistant Staphylococcus aureus: A multicenter study. Indian J Med Microbiol 2006;24:34-8.
14. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian A, Hujer AM, et al. Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patientsin Cleveland, Ohio. Antimicrob Agents Chemother 2011;55:1684-92.
15. Ikeda-Dantsuji Y, Hanaki H, Sakai F, Tomono K, Takesue Y, Honda J, et al. Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. J Infect Chemother 2011;17:45-51.
16. Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, et al. Clinical outbreak of Linezolid-resistant Staphylococcus aureus in an Intensive Care Unit. JAMA 2010;303:2260-4.
17. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for Linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009;64:191-201.
18. Farell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program Results for 2009: An Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. Antimicrob Agents Chemother 2011;55:3684-90.
19. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci in 25 UK hospitals to linezolid and other antimicrobial agents. J Antimicrob Chemother 2000;46:931-40.
20. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.
21. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998;42:721-8.
22. Anderegg TR, Biedenbach DJ, Jones RN. Recent In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Staphylococcal Isolates. Antimicrob Agents Chemother 2002;46:2662-4.
23. Locke JB, Morales G, Hilgers M, Kedar GC, Rahawi S, José Picazo J, et al. Elevated Linezolid Resistance in Clinical cfr-Positive Staphylococcus aureus isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3 . Antimicrob Agents Chemother 2010;54(Suppl12):5352-5.
24. Bell JM, Turnidge JD, Ballow CH, Jones RN; ZAPS Regional Participants. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J Antimicrob Chemother 2003;51:339-45.
25. Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: A European inter-country comparison. J Antimicrob Chemother 2001;48:47-52.
26. Ranjan KP, Arora DR, Ranjan N. An approach to Linezolid and vancomycin against Methicillin resistant Staphylococcus Aureus. Webmed Central MICROBIOLOGY 2010;1:WMCOO590.
27. Onur K, Fusun ZA, Esra NT. In Vitro Activities of Linezolid and Tigecycline Against Methicillin-Resistant Staphylococcus Aureus Strains. Microb Drug Resist 2008;14(Suppl2):151-3.
28. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000;45:225-30.
29. Arias CA, Vallejo M, Reyes J, Panesso D, Moreno J, Castaneda E, et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008;46:892-6.